Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study).

Acceptability, Tolerability and Safety of Faecal Microbiota Transplantation in patients with active Ulcerative Colitis (AT&S Study).

J Gastroenterol Hepatol. 2019 Aug 13;:

Authors: Sood A, Singh A, Mahajan R, Midha V, Mehta V, Gupta YK, Narang V, Kaur K

Abstract
BACKGROUND: Faecal microbiota transplantation (FMT) targets gut microbiome dysbiosis and is an emerging therapy for ulcerative colitis (UC). Though initial results with FMT in patients with active UC are encouraging, data regarding its acceptability, tolerability and safety are scant.
METHODS: A retrospective analysis of patients with active UC (Mayo clinic score ≥4), who received multisession FMT (at weeks 0, 2, 6, 10, 14, 18 and 22) via colonoscopy between June 2016 and June 2018, was done. Patient acceptability, tolerability and immediate and long term safety of the therapy were assessed.
RESULTS: Of the 129 patients with active UC who were offered FMT, 101 patients consented; giving acceptability of 78.3%. Faecal slurry retention time, improved with each session (3.27 ± 1.06 hours for first session vs 5.12 ± 0.5 hours for seventh session). Abdominal discomfort, flatulence, abdominal distension, borborygmi and low grade fever (30.8%, 15.9%, 9.8%, 7.9% and 7.6% respectively) were the most common post procedural short term adverse events. Long term adverse events included new-onset urticaria (n=2,4.3%), arthritis/arthralgias(n=3, 6.5%), depression (n=1, 2.2%), partial sensorineural hearing loss (n=1, 2.2%), and allergic bronchitis (n=1, 2.2%). Thirteen (12.9%) patients dropped out due to adverse events.
CONCLUSION: FMT appears to be a safe and well tolerated procedure, with good acceptability in patients with active UC.

PMID: 31408913 [PubMed – as supplied by publisher]

PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/31408913?dopt=Abstract